Your session is about to expire
← Back to Search
Atezolizumab + Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing the combination of atezolizumab and stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer.
- Nonsmall Cell Lung Cancer, Stage I
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have one or more characteristics that indicate a higher risk for a certain condition.You have other health conditions that are not being properly managed or controlled.You can participate in the study even if you have a history of low thyroid hormone levels that is being treated with medication.You had a serious infection within the last 4 weeks before joining the study.You have a history of lung conditions called idiopathic pulmonary fibrosis, drug-induced pneumonitis, or organizing pneumonia.You have never had a serious allergic reaction to other types of medications called monoclonal antibodies.You have a history of a disease where your immune system attacks your own body.You do not currently have any other types of cancer.
- Group 1: atezolizumab + SBRT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Food and Drug Administration sanctioned Atezolizumab?
"Due to the early stages of this clinical trial, our team at Power assigned Atezolizumab a score of 1 on safety. This is because there are limited data points that assess efficacy and safety."
Is this the inaugural endeavor of its kind?
"Atezolizumab has been under clinical investigations since 2008 when it was first sponsored by Hoffmann-La Roche. The initial study, involving 720 patients, earned the drug a Phase 2 approval. Currently, 350 active trials are being conducted across 74 countries and 1646 cities around the world."
For what medical conditions is Atezolizumab typically prescribed?
"Atezolizumab is a viable medical option for treating small cell lung cancer, in addition to malignant neoplasms and non-small cell lung carcinoma. This medication can also provide relief from postoperative pain."
How many participants are currently being administered treatment in this research endeavor?
"This clinical trial is no longer seeking new candidates. The study was initially published on February 1st 2016, and the last update was made on August 2nd 2022. For those searching for similar studies, 1909 medical trials recruiting participants with malignant neoplasms are available, along with 350 studies using Atezolizumab as an intervention actively enrolling patients."
Is recruitment of participants ongoing for this experiment?
"Per clinicaltrials.gov, this study is no longer recruiting participants, despite being initially posted on February 1st 2016 and last updated August 2nd 2022. Although the trial has closed to new recruits, there are currently 2259 other studies actively searching for patient volunteers."
Share this study with friends
Copy Link
Messenger